BRCA1 and breast cancer: The finding that BRCA1/2 deficient cells are highly sensitive to PARP inhibition [53] has opened a new avenue of research for treatment and prevention of tumors arising in the context of BRCA1/2 mutation or which might have somatic impairment of such pathways, such as basal-like breast cancer.